15.06.2018
Upcoming event: 37C Health Meeting Stavanger
Regenics AS attends the 37C "Digitalization in Health" meeting on June 19-20 of June 2018 at Forus Stavanger. CEO Henrik Lund, co-chairs the meeting    
13.06.2018
Regenics AS Annual Report 2017
Regenics post a small positive 2017 result with topline in excess of 0.047 mill NOK. 
13.06.2018
Notice of Annual Meeting June 28th 2018
June 13th 2018 Notice of Annual Meeting June 28th 2018. The Annual Meeting 2018 will take place at the Companys site Karvesvingen 2. 2, Oslo from 2 pm to 5 pm.
23.05.2018
Innovation Norway grants Innovation Contract to Regenics AS
Regenics AS was May 18th 2018 awarded an Innovation Contract from Innovation Norway. The Innovation Contract has a total budget of 14.3 million NOK to support the development of Vernex®...
07.05.2018
Updated share info May 7th 2018
Regenics AS provides updated share info and shareowner distribution as per May 7th 2018
03.01.2018
Protocol from Extraordinary Annual Meeting December 15th 2017
December 15th 2017 Protocoll of Extraordinary Annual Meeting December 15th 2017. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
03.01.2018
Succesfull placement of share issue December 2017
According to resolutions by the Board of Directors on December 15th 2017 a limited private placement of a total of 129.729 shares at a price of 17.15 NOK per share...
27.11.2017
Japan-US researchers shows pacific roe boosting collagen mRNA production in skin cells
Pacific chum salmon roe extracts show boosting of collagen I mRNA production in skin cells and induction of anti-oxidative genes.
06.11.2017
Phillippe Collas awarded research grant from the Norwegian Cancer Society
The Norwegian Cancer Society (kreftforeningen.no), has November 3rd 2017 awarded 6 mill NOK to Professor Philippe Collas, University of Oslo for the project (norwegian): "Nytt klassifiseringsverktøy for brystkreft".
18.10.2017
New SME Instrument 2 application submitted
October 18th 2017, Regenics submits its second  SME Instruments 2 funding application for Vernex® in psoriasis based on EU Commision Seal of Excellence" project obtained July 17th 2017.
04.10.2017
New Eurostars application for Regenics
September 18th 2017, Regenics submits its second  Eurostars R&D funding application for Vernex® in psoriasis based on EU Commision Seal of Excellence" project.
30.08.2017
EU Commision upgrades "Seal of Excellence" projects for funding
EU Commision urges national bodies to fund Horizon 2020 "Seal of Excellence" projects throug a press release of May 17th 2017
30.08.2017
Protocoll from Annual Meeting June 27th 2017
June 27th 2017 Protocoll of Annual Meeting June 27nd 2017. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
17.08.2017
Notice of Annual Meeting June 27nd 2017
June 20th 2017 Notice of Annual Meeting June 27nd 2017. The Annual Meeting 2016 will take place in the Companys office, Karvesvingen. 2, Oslo at 5 pm.
15.08.2017
Japan patent issued
Regenics marine technology has been granted Japanese patent on July 21st 2017
28.07.2017
Research Council grant PES 2020
Regenics AS was today awarded a contribution from the Research Council from the PES2020 program for an above treshold rating of its SME Instruments 2 application of June 2017.   

Page 1 of 5   >  >>

REGENICS AT EVENTS

June 5-6th 2017

Investor Conference Biotech-Medtech, at Stavanger Forum Oslo

Program (tbd)

March 9th 2017

Roundtable Conference in investing in Biotech, CEO Henrik Lund, moderator for the Event at Stavanger Forum Oslo

Program Roundtable Conference Stavanger

March 8th 2017

War on Cancer Nordics, CEO Henrik Lund participating in closing panel at the Economist Event in Oslo

Program Economist Event Oslo

December 15th 2016

DnB Healtcare Conference 2016, CMO Christian Clemm provides company update in the ventture session

Regenics presentation   

October 19-20-21 2016

Biomarine Convention, CEO Henrik Lund, participating at Convention in Oslo

Program Biomarine Business Conference

October 19th 2016

DnB Next at Oslo Innovation Week, CSO Gry Lønne, presenting Regenics Company update in Oslo

program DNB Next healthcare      Regenics presentation 

September 25-28 2016

At the 4th Congress on Innovation in Drug Delivery in Antibes, Regenics publish data on its carrier/vehicle GMO to be used in the CE marking device for wound healing.

Abstract 4th Congress on Innovation in Drug Delivery

October 22-24 2015

At the Joint Meeting of the European Tissue Repair Society (ETRS) and the Wound Healing Society (WHS), Regenics showed excellent and rapid wound healing of its wound healing device Vernex under development for CE-marking in 2018. In 2nd degree burn wounds Vernex provided rapid and complete reepitelialization of epidemal keratinocytes in human explanted skin. This represent a prooof of priciple for the utility of Vernex in human wound healing. 

Abstract 7th ETRS-WHS meeting

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.